FORM 10-QSB
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES AND EXCHANGE ACT OF 1934
For the quarterly period ended May 31, 1999
Commission File Number: 1-11140
OPHTHALMIC IMAGING SYSTEMS
(Exact name of registrant as specified in its charter)
California 94-3035367
(State of Incorporation) (IRS Employer Identification No.)
221Lathrop Way, Suite I, Sacramento, CA 95815
(Address of principal executive offices)
(916) 646-2020
(Issuer's telephone number, including area code)
Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes XX No
As of July 14, 1999, 4,155,428 shares of common stock, at no par value, were
outstanding.
<PAGE>1
ITEM 1. FINANCIAL STATEMENTS
<PAGE>2
Ophthalmic Imaging Systems
Condensed Balance Sheet
May 31, 1999
(Unaudited)
<TABLE>
<S> <C>
Assets
Current assets:
Cash and equivalents $ 147,226
Accounts receivable, net 1,067,203
Inventories, net 326,579
Prepaid expenses and other current assets 43,089
----------------------
Total current assets 1,584,097
Furniture and equipment, net of accumulated
depreciation and amortization of $992,959 324,508
Other assets 14,669
======================
$ 1,923,274
======================
Liabilities and Stockholders' Equity
Current liabilities:
Borrowings under line of credit $ 219,152
Borrowings under note payable to, and unsecured
advances from significant shareholder, net 1,288,991
Accounts payable 567,908
Accrued liabilities 1,226,635
Accrued warrant appreciation right 287,056
Deferred extended warranty revenue 92,056
Customer deposits 369,011
Capitalized lease obligation and other notes payable 8,939
----------------------
Total current liabilities 4,059,748
Capitalized lease obligation and other notes payable,
less current portion 20,251
Commitments
Stockholders' deficit:
Preferred stock, no par value, 20,000,000 shares authorized;
none issued or outstanding --
Common stock, no par value, 20,000,000 shares authorized;
4,155,428 issued and outstanding 10,462,604
Deferred compensation (113,185)
Accumulated deficit (12,506,144)
----------------------
Total stockholders' deficit (2,156,725)
======================
$ 1,923,274
======================
</TABLE>
See accompanying notes.
<PAGE>3
Ophthalmic Imaging Systems
Condensed Statements of Operations
(Unaudited)
<TABLE>
<S> <C> <C> <C> <C>
Three months ended May 31, Nine months ended May 31,
1999 1998 1999 1998
------------------- ------------------- -------------------- ----------------
Net revenues $ 1,655,610 $ 1,377,830 $ 5,005,897 $ 4,747,864
Cost of sales 869,533 935,690 2,919,939 3,252,117
------------------- ------------------- -------------------- -----------------
Gross Profit 786,077 442,140 2,085,958 1,495,747
Operating expenses:
Sales and marketing 459,353 478,778 1,384,893 1,431,835
General and administrative 209,568 538,645 733,360 1,792,003
Research and development 241,527 206,647 712,440 608,352
------------------- ------------------- -------------------- -----------------
Total operating expenses 910,448 1,224,070 2,830,693 3,832,190
------------------- ------------------- -------------------- -----------------
Loss from operations (124,371) (781,930) (744,735) (2,336,443)
Other expense, net (42,502) (15,199) (106,438) (44,078)
------------------- ------------------- -------------------- -----------------
Loss before extraordinary item (166,873) (797,129) (851,173) (2,380,521)
Extraordinary item 350,000 -- 350,000 --
=================== =================== ==================== =================
Net income (loss) $ 183,127 $ (797,129) $ (501,173) $ (2,380,521)
=================== =================== ==================== =================
Shares used in the calculation of basic
net income (loss) per share 4,155,428 4,155,428 4,155,428 3,989,687
=================== =================== ==================== =================
Basic loss per share before
extraordinary item $ (0.04) $ (0.19) $ (0.20) $ (0.60)
Extraordinary item 0.08 -- 0.08 --
=================== =================== ==================== =================
Basic net income (loss) per share $ 0.04 $ (0.19) $ (0.12) $ (0.60)
=================== =================== ==================== =================
Shares used in the calculation of diluted
net income (loss) per share 4,155,428 4,155,428 4,155,428 3,989,687
=================== =================== ==================== =================
Diluted loss per share before
extraordinary item $ (0.04) $ (0.19) $ (0.20) $ (0.60)
Extraordinary item 0.08 -- 0.08 --
=================== =================== ==================== =================
Diluted net income (loss) per share $ 0.04 $ (0.19) $ (0.12) $ (0.60)
=================== =================== ==================== =================
</TABLE>
See accompanying notes.
<PAGE>4
Ophthalmic Imaging Systems
Condensed Statements of Cash Flows
Increase (Decrease) in Cash and Equivalents
(Unaudited)
<TABLE>
<S> <C> <C>
Nine months ended May 31,
1999 1998
---------------------- -----------------------
Operating activities:
Net loss $ (501,173) $ (2,380,521)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 85,277 95,812
Stock option compensation expense 78,115 97,375
Net (increase) decrease in current assets
other than cash and equivalents (399,292) 596,477
Net increase in current liabilities
other than short-term borrowings 245,842 753,406
---------------------- -----------------------
Net cash (used in) provided by operating activities (491,231) (837,451)
Investing activities:
Purchases of furniture and equipment 1,607 (147,721)
Net increase in other assets (7,284) (11,387)
---------------------- -----------------------
Net cash used in investing activities (5,677) (159,108)
Financing activities:
Principal payments on notes payable (318) (2,048)
Net proceeds from borrowings under note payable to
and unsecured advances from significant shareholder 9,289 910,027
Net proceeds from (repayments of) line-of-credit
borrowings 120,977 (185,855)
Net proceeds from sale of common stock -- 213,750
---------------------- -----------------------
Net cash provided by financing activities 129,948 935,874
---------------------- -----------------------
Net decrease in cash and equivalents (366,960) (60,685)
Cash and equivalents at beginning of period 514,186 142,300
====================== =======================
Cash and equivalents at end of period $ 147,226 $ 81,615
====================== =======================
Supplemental schedule of noncash financing activities:
Reduction of borrowing under note payable to and
unsecured advances from significant shareholder
in exchange for inventory $ 182,778 $ --
====================== =======================
</TABLE>
See accompanying notes.
<PAGE>5
Ophthalmic Imaging Systems
Notes to Condensed Financial Statements
Three and Nine Month Periods ended May 31, 1999 and 1998
(Unaudited)
Note 1. Basis of Presentation
The accompanying unaudited condensed balance sheet as of May 31,
1999, condensed statements of operations for the three and nine
month periods ended May 31, 1999 and 1998 and the condensed
statements of cash flows for the three and nine month periods
ended May 31, 1999 and 1998 have been prepared in accordance
with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-QSB
and Item 310(b) of Regulation S-B. Accordingly, they do not
include all of the information and footnote disclosures required
by generally accepted accounting principles for complete
financial statements. It is suggested that these condensed
financial statements be read in conjunction with the audited
financial statements and notes thereto included in the
registrant's (the Company's) Annual Report for the Fiscal Year
Ended August 31, 1998 on Form 10-KSB. In the opinion of
management, the accompanying condensed financial statements
include all adjustments, consisting only of normal recurring
adjustments, necessary for a fair presentation of the Company's
financial position and results of operations for the periods
presented. The results of operations for the period ended May
31, 1999 are not necessarily indicative of the operating results
for the full year.
Certain amounts in the fiscal 1998 financial statements have
been reclassified to conform with the presentation in the fiscal
1999 financial statements.
Note 2. Net Income (Loss) Per Share
In 1997, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards No. 128, "Earnings
per Share". Statement 128 replaced the previously reported
primary and fully diluted earnings per share with basic and
diluted earnings per share. Unlike primary earnings per share,
basic earnings per share excludes any dilutive effects of
options, warrants, and convertible securities. Diluted earnings
per share is very similar to the previously reported fully
diluted earnings per share. All net income (loss) per share
amounts for all periods have been presented, and where
necessary, restated to conform to the Statement 128
requirements.
<PAGE>6
Note 2. Net Income (Loss) Per Share (continued)
The following table sets forth the computation of basic and
diluted income (loss) per share:
<TABLE>
<S> <C> <C> <C> <C>
Unaudited Unaudited
Three Months Ended Nine Months Ended
May 31, May 31,
1999 1998 1999 1998
=============== ============ ============== =============
Numerator for basic and diluted
net income (loss) per share $ 183,128 $ (797,129) $ (501,171) $ (2,380,521)
=============== ============ ============== =============
Denominator for basic net income
(loss) per share:
Weighted average shares 4,155,428 4,155,428 4,155,428 3,989,687
Effect of dilutive securities:
Employee/director stock
options -- -- -- --
Warrants and other -- -- -- --
--------------- ------------ -------------- -------------
Dilutive potential common shares -- -- -- --
=============== ============ ============== =============
Denominator for diluted net
income (loss) per share 4,155,428 4,155,428 4,155,428 4,155,428
=============== ============ ============== =============
Basic net income (loss) per share $ .04 $ (0.19) $ (0.12) $ (0.60)
=============== =============== ============== ===============
Diluted net income (loss) per
share $ .04 $ (0.19) $ (0.12) $ (0.60)
=============== =============== ============== ===============
</TABLE>
Note 3. Short-Term Borrowings
In April 1995, the Company entered into a revolving line of
credit agreement (the "Credit Agreement") with its bank (the
"Bank") which, after several amendments, matured in November
1997.
In November 1997, the Company entered into an accounts
receivable credit agreement (the "Agreement") with the Bank, and
all amounts outstanding under the Credit Agreement were
considered to be the initial advance under the Agreement. The
Agreement allows for up to an 80% advance rate on eligible
accounts receivable balances, and the maximum borrowing base
under the Agreement is $1.2 million. The Bank has full recourse
against the Company and the Agreement remains in effect from
year to year unless terminated in writing by the Company or the
Bank. Borrowings under the Agreement bear interest at the Bank's
prime lending rate plus 4%. In addition, the Bank will charge
monthly an administrative fee equal to the greater of 1/2% of
the average daily balance for the month or $1,200. Under the
terms of the Agreement, borrowings are secured by substantially
all of the Company's assets. At May 31, 1999, approximately
$219,152 in principal was outstanding under the Agreement.
<PAGE>7
Note 4. Note Payable to Related Party
On April 30, 1998, the Company executed a promissory note (the
"Note") in favor of Premier Laser Systems, Inc., a California
corporation ("Premier"). Borrowings against the Note are
available to the Company in the form of periodic advances. The
maximum principal amount available under the Note is $500,000,
which principal amount outstanding, together with any and all
accrued interest, is payable the earlier of (i) written demand
by Premier or (ii) April 30, 1999. Under the terms of the Note,
borrowings bear interest at the rate of 8 1/2% per annum, are
secured by certain of the Company's assets and are subordinate
to borrowings against the accounts receivable credit line with
the Company's Bank (see Note 3). Premier also has made certain
unsecured advances to the Company which are not covered by the
Note.
At May 31, 1999, the Company had recorded approximately
$1,591,000 in principal and interest outstanding under the Note
and unsecured advances, which amount was reduced to
approximately $1,408,000 by an offset in the amount of
approximately $183,000 pursuant to the terms of the
Manufacturing Agreement described in Note 5. While the amounts
owing under the Note are currently due, Premier has not made
demand for payment and the Company and Premier have been in
discussions, among other things, to establish mutually
acceptable repayment terms. In that connection, there is
disagreement between Premier and the Company as to whether the
Company is entitled to the $500,000 Termination Fee and whether
such Termination Fee can be used as an offset to the Company's
debt to Premier.
Note 5. Manufacturing Agreement
In March 1999, the Company and Premier entered into a
manufacturing agreement ("Manufacturing Agreement") whereby
Premier will manufacture the majority of the Company's products.
The Manufacturing Agreement will terminate upon the earlier of:
(i) material breach by either party, which breach is not cured
within thirty (30) days written notice thereof; (ii) ninety (90)
days written notice by the Company to Premier; (iii) one hundred
eighty (180) days written notice by Premier to the Company; or
(iv) mutual written agreement of the parties.
At May 31, 1999, the Company recorded a charge of approximately
$183,000, which amount was offset against the unsecured advances
made to the Company by Premier. This amount represents inventory
transferred to Premier pursuant to the Manufacturing Agreement,
net of charges from Premier to the Company for products
manufactured pursuant to the Manufacturing Agreement.
<PAGE>8
Note 6. Stock Purchase Agreement
In August 1998, the Company was notified by Premier that Premier
would be unable to proceed with its previously proposed
acquisition of the remaining 48.7% interest in the Company by
the termination date of the Stock Purchase Agreement, dated
February 25, 1998, with the Company ("Stock Purchase
Agreement"). As a result, the Stock Purchase Agreement was
terminated and the Company made a demand for payment from
Premier of $500,000 as a termination fee (the "Termination Fee")
pursuant to the Stock Purchase Agreement. The Termination Fee,
however, is the subject of a disagreement between the companies.
Accordingly, the Company has not recognized the Termination Fee
in its financial statements.
Note 7. Extraordinary Item
In May 1999, the Company reached agreement with a financial
advisor to significantly reduce the aggregate amount of
professional fees and expenses previously recorded in connection
with the terminated Stock Purchase Agreement with Premier.
Note 8. Subsequent Event
In June 1999, the Company received a merger proposal from
Premier. The offer called for an exchange of Premier common
stock for Company common stock on the basis of $.85 in value of
Premier common stock for each share of Company common stock. The
offer was subject to negotiation of a definitive merger
agreement containing customary representations and warranties
and conditions to closing, including: (i) absence of material
adverse change in either party; (ii) approval by at least 75% of
the Company shares (i.e., a majority of the shares not presently
owned by Premier); and (iii) the Company's obtaining a "fairness
opinion" with respect to the proposed transaction.
The Company rejected the offer as inadequate. However, to assist
the Company in evaluating any subsequent offers received for the
Company or its stock, the Company engaged the services of an
investment banker and legal counsel. To date, the Company has
not received any subsequent offers.
<PAGE>9
Note 9. Ability to Continue as a Going Concern
The Company has an accumulated deficit of $12,506,144 at May 31,
1999. In addition, current liabilities exceed current assets by
$2,475,651 as of that date. These factors, among others, raise a
question whether the Company is able to continue as a going
concern.
The principal and accrued interest on the Note, by its terms,
were due and payable on April 30, 1999. As of the date hereof,
the Company has not made any payments under the Note. Although
Premier has indicated its willingness to negotiate a repayment
schedule and defer any default proceedings, there can be no
assurance that such negotiations will be successful and that the
terms of the Note will be revised or that default proceedings
will be deferred. In addition, even if the Note is renegotiated,
there can be no assurances that it will be on terms acceptable
to the Company or that the Company will thereafter be able to
generate sufficient liquidity from operations to meet its
obligations as they become due.
The Company is seeking sources of additional capital to meet its
current cash requirements, including debt and other financing
arrangements. There can be no assurance, however, that any
financing arrangements will be available and, if available, can
be obtained on terms favorable to the Company.
<PAGE>10
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The statements below include statements that are "forward looking statements"
within the meaning of Section 21A of the Securities Act of 1933, as amended, in
Section 21E of the Securities Act of 1934, as amended, and is subject to the
safe harbor created thereby. Future operating results may be adversely effected
as a result of a number of factors enumerated in the Company's public reports.
Overview
The Company has designed, developed, manufactured and marketed ophthalmic
digital imaging systems and has derived substantially all of its revenues from
the sale of such products. The primary target market for the Company's digital
angiography systems has been the retinal specialists who number approximately
2,000 in the United States (approximately 12%-13% of ophthalmologists in the
U.S.).
OIS is currently attempting to expand its role in the ophthalmic imaging field
by developing new ocular imaging devices and applications targeted at the
broader markets of general ophthalmology and optometry.
In this regard, commencing in fiscal 1998, the Company has applied significant
resources to the development of two ocular imaging devices, the Digital Fundus
Imager ("DFI") and the Digital Slit Lamp Imager ("DSLI"). These two new
products, which were introduced at the Annual Meeting of the American Academy of
Ophthalmology (the "AAO") in November 1998 (the "1998 AAO Meeting"), provide the
general ophthalmology and optometry markets with affordable diagnostic digital
imaging devices. The Company is focusing the majority of its current
development, marketing and sales efforts on its DFI and DSLI products, and
anticipates that it will commence delivering these products during the fourth
quarter of fiscal 1999.
At the 1998 AAO Meeting, the DFI received considerable interest and the Company
has received significant purchase commitments for the product. However, the
Company has limited financial and operational resources, including
manufacturing, marketing and selling capacity to meet any increased demand that
may result from the successful introduction of this product. During the recently
completed third quarter ended May 31, 1999, the Company entered into a
manufacturing agreement ("the Manufacturing Agreement") with Premier Laser
Systems, Inc. ("Premier"), a California corporation and holder of approximately
51.3% of the Company's outstanding common stock whereby Premier will manufacture
the Company's products, including the DFI and DSLI. Initial deliveries of
revenue generating products manufactured by Premier under the Manufacturing
Agreement were made during the quarter. The Company entered into the
Manufacturing Agreement to reduce the cost of manufacturing the Company's
products and to take advantage of Premier's manufacturing capabilities. Based on
the limited experience to date under the terms of the Manufacturing Agreement,
there can be no assurance that this arrangement will provide the Company the
anticipated benefits.
<PAGE>11
In addition, the Company also is negotiating an agreement with Premier on a
co-marketing and selling arrangement. The Company is seeking an arrangement with
Premier whereby: (a) the Company's sales force would have additional products to
sell, including Premier's EyeSys product line; (b) the Company access to
Premier's international distribution channels; and (c) the Company could benefit
from the EyeSys products' reputation among general ophthalmologists and
optometrists. Management believes that such an arrangement should also result in
certain cost efficiencies to the Company. In that regard and in anticipation
that an acceptable agreement will be reached, the Company and Premier have been
selling their optical products through a jointly managed EyeSys Vision Group.
The EyeSys Vision Group made its debut at the American Society of Cataract and
Refractive Surgery meeting ("ASCRS") in April 1999, at which the Company
received significantly more purchase commitments than at previous ASCRS
meetings, predominantly for the DFI and DSLI products. While the Company is
optimistic that an agreement with Premier in this regard will be executed
shortly, there can be no assurance that an acceptable agreement, if any, will be
reached.
The Company continues to experience a cash flow deficit and its liabilities
currently exceed its assets. In this regard, the Company's recorded debt to
Premier, as of May 31, 1999, exceeded $1.4 million. The Company is seeking
additional sources of financing. The Company also is hopeful that it can
generate revenues from sales of its DFI and DSLI products sufficient to: (a)
fund the production and distribution of these and current products; and (b)
enable the Company to begin to pay down the debt to Premier under a mutually
acceptable repayment plan with Premier. There can be no assurance, however, that
there will be favorable market acceptance of these products sufficient to
generate needed revenues or that a mutually acceptable repayment plan, if any,
can be reached with Premier.
Notwithstanding the initiatives discussed above, there can be no assurance that
the Company will be successful in such efforts or that any contemplated
arrangements can be obtained on terms favorable to the Company. Failure to
achieve one or more of these objectives may have an adverse effect on the
Company's ability to continue as a going concern or realize the full potential
benefits from timely delivery of its new products.
In June 1999, the Company received a merger proposal from Premier. The offer
called for an exchange of Premier common stock for Company common stock on the
basis of $.85 in value of Premier common stock for each share of Company common
stock. The offer was subject to negotiation of a definitive merger agreement
containing customary representations and warranties and conditions to closing,
including: (i) absence of material adverse change in either party; (ii) approval
by at least 75% of the Company shares (i.e., a majority of the shares not
presently owned by Premier); and (iii) the Company's obtaining a "fairness
opinion" with respect to the proposed transaction.
The Company rejected the offer as inadequate. However, to assist the Company in
evaluating any subsequent offers received for the Company or its stock, the
Company engaged the services of an investment banker and legal counsel. To date,
the Company has not received any subsequent offers and there can be no assurance
any such offer or offers will be received in the future.
The Company's results of operations have historically fluctuated from quarter to
quarter due to a number of factors and are not necessarily indicative of the
<PAGE>12
results to be expected for any future period or expected for the fiscal year
ending August 31, 1998. There can be no assurance that revenue growth or
profitability can be achieved or sustained in the future.
The following discussion should be read in conjunction with the unaudited
interim financial statements and the notes thereto which are set forth elsewhere
in this Report on Form 10-QSB. In the opinion of management, the unaudited
interim period financial statements include all adjustments, all of which are of
a normal recurring nature, that are necessary for a fair presentation of the
results of the periods.
Results of Operations
The Company recorded net income of $183,128, or $.04 per share, for the third
quarter of fiscal 1999 as compared to a net loss of $797,129, or $.19 per share,
for the third quarter of fiscal 1998. The Company incurred a net loss of
$501,171, or $.12 per share, for the first nine months of 1999 versus a net loss
of $2,380,521, or $.60 per share, for the comparable period of 1998. The 1999
figures for both the third quarter and the nine-month period include an
extraordinary gain of $350,000, or $.08 per share, resulting from the negotiated
reduction of certain professional fees and expenses previously recorded in
connection with the terminated Stock Purchase Agreement with Premier.
The per share figures are basic amounts in accordance with Financial Accounting
Standards No. 128 (see Note 2 of Notes to Condensed Financial Statements
included in Item 1 of this Form 10-QSB).
The 1998 loss reflects the adverse impact on revenues and corporate operations
resulting from efforts associated with the terminated Stock Purchase Agreement,
including significant costs and professional fees and expenses in connection
therewith. Principal contributing factors to the significantly reduced loss in
1999 were a substantial reduction in those acquisition expenses and the positive
impact of the extraordinary item. Nevertheless, some negative impact on earnings
was attributable to continuing diversion of the Company's resources and
management's attention to acquisition matters in 1999.
The Company's revenues for the third quarter of fiscal 1999 were $1,655,610,
representing an increase of approximately 20% from revenues of $1,377,830 for
the third quarter of fiscal 1998. Revenues for the first nine months of fiscal
1999 were $5,005,897, representing an increase of approximately 5% from revenues
of $4,747,864 for the comparable period of 1998. The increase in revenues in the
1999 third quarter and nine-month periods as compared to the respective 1998
periods was due principally to lower than normal revenues during the 1998
periods. During the 1998 third quarter, the Company deferred delivery of units
against several orders pending the completion of certain software upgrades,
which upgrades were completed toward the end of the 1998 third quarter.
Additionally, the 1998 third quarter and nine-month revenues were adversely
impacted by the redirection of management's efforts from core operations to its
negotiations with Premier.
<PAGE>13
During the 1998 AAO Meeting, the Company introduced its low-cost digital imaging
systems incorporating its recently developed ocular imaging devices, the DFI and
the DSLI. The Company received substantially more purchase commitments for its
products as compared to previous AAO meetings, with significant purchase
commitments for the newly introduced products, deliveries of which newly
introduced products are currently targeted to commence during the fourth quarter
of fiscal 1999.
Gross margins were approximately 47% during the third quarter ended May 31, 1999
versus approximately 32% for the comparable quarter of 1998. For the nine-month
period ended May 31, 1999, gross margins were approximately 42% as compared to
approximately 32% during the comparable period of 1998. The increase in gross
margin percentage during the third quarter was partially attributable to the
significantly increased revenue levels during the third quarter of 1999 and the
reversal of certain reserves accrued in 1998 for potential field upgrades. In
addition, the lower gross margins for the 1998 third quarter reflect the adverse
impact of increased reserves for potential field upgrades recognized for certain
systems delivered during the 1998 third quarter. Further, the increase in such
reserves for systems delivered during the first nine months of 1998 was a
principal factor for the lower gross margins for the nine-month period of 1998
as compared to the same period for 1999. The Company continues to evaluate its
expenses in this area consistent with current and anticipated business
conditions. During the recently completed third quarter, the Company entered
into a Manufacturing Agreement with Premier which management anticipates will
provide certain efficiencies which may result in improved gross margins. While
initial deliveries of revenue generating products manufactured by Premier under
the Manufacturing Agreement were made during the recently completed third
quarter ended May 31, 1999, this is a new arrangement and its impact is not
clearly ascertainable at this time.
As a percentage of revenues, sales and marketing and general and administrative
expenses accounted for approximately 40% of total revenues during the third
quarter of fiscal 1999 versus approximately 74% of total revenues during the
comparable third quarter of fiscal 1998. For the first nine months of fiscal
1999 and fiscal 1998, such expenses accounted for approximately 42% and 68% of
total revenues for the respective nine-month periods. Expense levels also
decreased to $668,921 during the third quarter of 1999 versus $1,017,423 during
the third quarter of 1998. For the first nine months of 1999, expense levels
decreased to $2,118,253 from $3,223,838 during the comparable period of 1998.
The 1998 sales and marketing and general and administrative expenses were
abnormally high in relation to revenues because of significant investment
banking, legal and other professional costs recognized during the second and
third quarters of 1998 associated with the negotiation of the Stock Purchase
Agreement. In 1999, such expenses returned to more normal levels due to the
termination of the Stock Purchase Agreement. In addition, the 1999 amounts
reflect the cost reductions realized from the termination of certain management
personnel during the latter half of 1998. The Company is currently implementing
marketing and selling alternatives in an effort to reduce costs and/or improve
efficiencies in this area, including consolidating its current product offerings
and co-marketing and selling efforts.
Research and development expenses, as a percentage of revenues, were
approximately 15% in both the third quarter of 1999 and the third quarter of
<PAGE>14
1998. For the first nine months of fiscal 1999, such expenses accounted for
approximately 14% of total revenues as compared to approximately 13% during the
comparable period of 1998. Expense levels increased in actual dollar terms to
$241,527 during the third quarter of 1999 from $206,647 in 1998. During the
first nine months of fiscal 1999, expense levels also increased in actual dollar
terms to $712,440 versus $608,352 in 1998. The Company intends to continue to
focus its research and development efforts on its new digital image capture
products and reducing cost configurations for its current products. The Company
anticipates that research and development expense will be maintained at or above
current levels in the immediate term.
Other expense was $42,502 during the third quarter of fiscal 1999 versus $15,199
during the second quarter of 1998. For the first nine months of 1999 and 1998,
other expense was $106,438 and $44,078, respectively. The primary contributing
factor to these increases was interest expense during 1999 versus 1998
associated with borrowings and unsecured advances from Premier, which borrowings
and unsecured advances were made after the first quarter of 1998 (see Note 4 of
Notes to Condensed Financial Statements included in Item 1 of this Form 10-QSB).
Liquidity and Capital Resources
The Company's operating activities used cash of $491,231 during the first nine
months of fiscal 1999 and $837,451 during the comparable period for 1998. The
cash used in operations during the first nine months of 1999 was expended
principally to fund the net loss during the period and the increase in accounts
receivable associated with timing of product deliveries toward the end of the
period. This amount was partially offset by increases in customer deposits. Cash
used in operating activities in the first nine months of 1998 was expended
principally to fund the net loss during the period. This amount was partially
offset by collection of accounts receivable and increases in customer deposits
and accrued liabilities, particularly those liabilities accrued in conjunction
with significant investment banking, legal and other professional costs
recognized during the second and third quarters of 1998 associated with the
negotiation of the Stock Purchase Agreement.
Cash used in investing activities was $5,677 during the first nine months of
1999 as compared to $159,108 during the same period for 1998. The Company's
primary investing activities consist of equipment and other capital asset
acquisitions. The Company does not currently have any pending material
commitments for capital expenditures and the Company has deferred significant
capital acquisition decisions pending improved cash flow.
The Company generated cash from financing activities in the amount of $129,948
during the first nine months of fiscal 1999 as compared to $935,874 during the
same period of fiscal 1998. The source of cash from financing activities during
the 1999 period was principally proceeds from increased borrowings under the
credit facility with Imperial Bank (the "Bank") and, to a lesser extent, an
increase in the amount of borrowings under the note payable to and unsecured
advances by Premier. The sources of cash from financing activities in 1998 were
the net proceeds from the exercise of certain warrants issued pursuant to a
<PAGE>15
private placement of the Company's common stock in November 1995, borrowings
under the Note and unsecured advances from Premier. These amounts were partially
offset by net repayments of borrowings under the credit facility with the Bank.
Principal repayments on notes payable was negligible in both 1999 and 1998.
In November 1997, the Company entered into an accounts receivable credit
agreement (the "Agreement") with the Bank, and all amounts outstanding under a
matured revolving line of credit agreement with the Bank were considered to be
the initial advance under the Agreement. The Agreement allows for up to an 80%
advance rate on eligible accounts receivable balances, and the maximum borrowing
base under the Agreement is $1.2 million. The Bank has full recourse against the
Company and the Agreement remains in effect from year to year unless terminated
in writing by the Company or the Bank. Borrowings under the Agreement bear
interest at the Bank's prime lending rate plus 4%. In addition, the Bank will
charge monthly an administrative fee equal to the greater of 1/2% of the average
daily balance for the month or $1,200. Under the terms of the Agreement,
borrowings are secured by substantially all of the Company's assets. At May 31,
1999, approximately $219,000 in principal was outstanding under the Agreement.
Additionally, on April 30, 1998, the Company executed a promissory note in favor
of Premier (the "Premier Note"). The Company has borrowed the maximum principal
amount of $500,000 available under the Premier Note, which principal amount
outstanding, together with any and all accrued interest, was payable the earlier
of (i) written demand by Premier or (ii) April 30, 1999. Under the terms of the
Premier Note, borrowings bear interest at the rate of 8 1/2% per annum, are
secured by certain of the Company's assets and are subordinate to borrowings
under the Agreement with the Bank as described in the immediately preceding
paragraph. Premier also has made certain unsecured advances to the Company which
are not specifically covered by the Premier Note. At May 31, 1999, the Company
had recorded approximately $1,591,000 in principal and interest outstanding
under the Note and unsecured advances, which amount was reduced to approximately
$1,408,000 by an offset in the amount of approximately $183,000 pursuant to the
terms of the Manufacturing Agreement (see Note 5 of Notes to Condensed Financial
Statements included in Item 1 of this Form 10-QSB). While amounts under the
Premier Note are due and have not yet been paid by the Company, Premier has not
yet made demand for payment. The Company is hopeful that it will be able to
negotiate a repayment plan with Premier to avoid any default, but there can be
no assurance that a final agreement between the parties can be reached. In the
event that an agreement cannot be reached and demand for payment is made by
Premier, then the Company's ability to continue as a going concern could be
seriously jeopardized, and would depend upon its ability to obtain new financing
to repay the debt to Premier.
At May 31, 1999, the Company's cash and cash equivalents were $147,226. Assuming
that no demand is made for payment of amounts owing under the Premier Note, the
Company believes that its existing cash balances together with ongoing
collections of its accounts receivable and available borrowing capacity under
the Agreement will be adequate to meet its liquidity and capital requirements in
the near term. However, such amounts may not be sufficient if there is a
substantial delay in the mass introduction of the DFI and DSLI products, which
delay would result in reduced anticipated cash flow from sales of such products
as well as potential increased costs associated therewith. Further, demand for
<PAGE>16
payment by the Bank of amounts claimed pursuant to a stock appreciation right
granted to the Bank in connection with a credit arrangement between the Bank and
the Company also could result in the need for additional cash. At May 31, 1999,
the Company had accrued approximately $287,000 in liability under the stock
appreciation right. If there is a substantial delay in the introduction of the
Company's new products or the Company is required to make payment of the stock
appreciation right in full, then the Company would have to seek financing.
Further, although the Company may have the ability to manufacture and market its
DFI and DSLI products, without an infusion of capital or other improvements in
its liquidity position, the Company may have difficulty in meeting any
significant demand for these products.
The Company, however, is continuing to seek sources of additional capital to
meet its current and potential cash requirements, including debt and other
financing arrangements. There can be no assurance that any financing
arrangements will be available and, if available, can be obtained on terms
favorable to the Company.
<PAGE>17
PART II OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 2. CHANGES IN SECURITIES
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
As indicated in Note 4 of the Notes to Condensed Financial
Statements, and addressed further in the Liquidity and
Capital Resources discussion of Item 2 of Part I of this
report, the Company is in default of its principal and
interest payment obligations under the Note with Premier.
In addition, the Company also has recorded liability to
Premier for unsecured advances made to the Company by
Premier.
The aggregate amount recorded as liability at May 31, 1999
under the Note and unsecured advances, including principal
and interest, was approximately $1,591,000, which amount was
reduced to approximately $1,408,000 by an offset in the
amount of approximately $183,000 pursuant to the terms of
the Manufacturing Agreement described in Note 5 of the Notes
to Condensed Financial Statements.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITIES
None.
ITEM 5. OTHER INFORMATION
In May 1999, the Company granted to each of its non-employee
directors options to purchase up to 50,000 shares (or
200,000 shares in the aggregate of all directors) of the
Company's common stock at an exercise price of $0.375 per
share. In that connection, the options granted in January
1999 in similar amounts were cancelled. The options granted
in May 1999 were granted pursuant the Company's 1997
Nonstatutory Stock Option Plan and are subject to certain
vesting requirements. None of these options have been
exercised as of the date hereof.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) The exhibits listed on the accompanying Index to
Exhibits below are filed as a part hereof and are
incorporated by reference as noted.
(b) None.
<PAGE>18
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
undersigned has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
OPHTHALMIC IMAGING SYSTEMS
(Registrant)
By: /s/ STEVEN R. VERDOONER
-----------------------------------
Steven R. Verdooner,
Chief Executive Officer
By: /s/ STEVEN C. LAGORIO
----------------------------------
Steven C. Lagorio,
Chief Financial Officer (principal
accounting officer)
Dated: July 14, 1999
<PAGE>19
INDEX TO EXHIBITS
<TABLE>
<S> <C> <C>
Exhibit Number Footnote
Description of Exhibit Reference
2.1 Stock Purchase Agreement, dated as of February 25, 1998, by and between Registrant (13)
and Premier Laser Systems, Inc.
3.1 Articles of Incorporation of the Registrant, as amended. *
3.1(a) Amendment to Articles of Incorporation (Certificate of Determination of Preferences (11)
of Series A Junior Participating Preferred Stock of Ophthalmic Imaging Systems).
3.2 Amended Bylaws of the Registrant. *
3.3 Amendment to Amended Bylaws of the Registrant dated January 28, 1998. (16)
4.1 See Exhibits 3.1 and 3.2 for provisions of the Articles of Incorporation, as amended, *
and the amended Bylaws of the Registrant defining the rights of holders of common
stock of the Registrant.
4.2 Specimen of Stock Certificate. *
4.3 Rights Agreement, dated as of December 31, 1997, between Registrant and American (10)
Securities Transfer, Inc., including form of Rights Certificate attached thereto.
4.4 Amendment to Rights Agreement, dated as of February 25, 1998, between Registrant and (14)
American Securities Transfer, Inc.
10.1 Lease Agreement, dated as of July 10, 1987, between the Registrant (as tenant) and *
Transamerica/Emkay Income Properties I, as amended on July 23, 1990 and June 11, 1991.
10.1(a) Seventh Amendment to lease effective as of July 18, 1996. (7)
10.2 Employment Agreement, dated March 27, 1992, between the Registrant and Dennis J. *
Makes.
10.2(a) Amendment dated June 30, 1993 to the Employment Agreement between the Registrant and (1)
Dennis J. Makes dated March 27, 1992.
10.3 Confidentiality Agreement, dated March 27, 1992 between the Registrant and Dennis J. *
Makes.
10.4 Confidentiality Agreement, dated March 27, 1992 between the Registrant and Steven R. *
Verdooner.
10.5 Confidentiality Agreement, dated March 27, 1992 between the Registrant and Richard *
Wullaert.
10.6 Consulting Agreement, dated January 23, 1992, between the Registrant and G. Peter *
Halberg, M.D.
10.7 Assignment dated October 23, 1990 of U.S. Patent Application for Apparatus and Method *
for Topographical Analysis of the Retina to the Registrant by Steven R. Verdooner,
Patricia C. Meade, and Dennis J. Makes (as recorded on Reel 5490, Frame 423 in the
Assignment Branch of the U.S. Patent and Trademark Office).
10.8 Form of International Distribution Agreement used by the Registrant and sample form *
of End User Software License Agreement.
10.9 Original Equipment Manufacturer Agreement, dated April 1, 1991, between the Registrant
and SONY Medical Electronics, a division of SONY Corporation of America. *
10.10 Original Equipment Manufacturer/Value Added Reseller Agreement, dated May 7, 1991, *
between the Registrant and Eastman Kodak Company.
10.11 The Registrant's 1992 Nonstatutory Stock Option Plan and sample form of Nonstatutory *
Stock Option Agreement.
10.12 Cross-Indemnification Agreement, dated February 14, 1991, among Dennis Makes, Steven *
Verdooner, and Richard Wullaert.
10.13 Key Man Life Insurance Policies in the amount of $1,000,000 for each of Dennis J. Makes *
and Steven R. Verdooner, with the Registrant as the named beneficiary.
10.14 Stock Option Plan. (1)
10.15 Rental Agreement dated May 1, 1994 by and between the Registrant and Robert J. (2)
Rossetti.
10.16 Security and Loan Agreement (with Credit Terms and Conditions) dated April 12, 1995 (3)
by and between the Registrant and Imperial Bank.
10.16(a) General Security Agreement dated April 12, 1995 by and between the Registrant and (3)
Imperial Bank.
10.16(b) Warrant dated November 1, 1995 issued by the Registrant to Imperial Bank to purchase (4)
67,500 shares of common stock.
10.16(c) Amended Loan and Security Agreement (with Credit Terms and Conditions) dated November (4)
1, 1995.
10.16(d) Registration Rights Agreement dated November 1, 1995 between the Registrant and (4)
Imperial Bank.
10.16(e) Amended Loan and Security Agreement (with Credit Terms and Conditions) dated April 4, (6)
1996.
10.16(f) Amended Loan and Security Agreement (with Credit Terms and Conditions) dated July 12, (7)
1996.
10.16(g) Amended Loan and Security Agreement (with Credit Terms and Conditions) dated November (7)
21, 1996.
10.16(h) Amended Loan and Security Agreement (with Credit Terms and Conditions) dated June 3, (8)
1997.
10.16(i) Amended Loan and Security Agreement (with Credit Terms and Conditions) dated August (9)
28, 1997.
10.16(j) Amended Loan and Security Agreement (with Credit Terms and Conditions) dated October (9)
24, 1997.
10.16(k) Amended Loan and Security Agreement (with Credit Terms and Conditions) dated November (9)
3, 1997.
10.16(l) Amended Loan and Security Agreement (with Credit Terms and Conditions) dated November (9)
21, 1997.
10.16(m) Agreement of Purchase of Receivable (Full Recourse) dated November 18, 1997 between (9)
Registrant and Imperial Bank.
10.17 Employment Agreement dated November 20, 1995 between the Registrant and Steven R. (4)
Verdooner.
10.17(a) Amendment dated effective July 14, 1997 to Employment Agreement dated November 20, (16)
1995 between the Registrant and Steven R. Verdooner.
10.18 The Registrant's 1995 Nonstatutory Stock Option Plan and sample form of Nonstatutory (5)
Stock Option Agreement.
10.19 The Registrant's 1997 Nonstatutory Stock Option Plan and sample form of Nonstatutory (12)
Stock Option Agreement.
10.20 Promissory Note dated April 30, 1998 from the Registrant to Premier Laser Systems, (15)
Inc. in the maximum amount of $500,000 due in full upon the earlier of (i) written
demand by Premier or (ii) April 30, 1999.
10.21 Security Agreement dated April 30, 1998 by and between the Registrant and Premier (15)
Laser Systems, Inc.
10.22 Form of Indemnification Agreement dated January 23, 1998 between the Registrant and (16)
each of its directors, officers and certain key employees.
10.23 Manufacturing Agreement dated March 7, 1999 between the Registrant and Premier Laser (17)
Systems, Inc.
27 Financial Data Schedule (for SEC use only). (18)
</TABLE>
* Incorporated by reference to the Registrant's Registration Statement on
Form S-18, number 33-46864-LA.
(1) Incorporated by reference to the Registrant's Annual Report on Form 10-KSB
for the fiscal year ended August 31, 1993 filed on November 26, 1993.
(2) Incorporated by reference to the Registrant's Annual Report on Form 10-KSB
for the fiscal year ended August 31, 1994 filed on November 29, 1994.
(3) Incorporated by reference to the Registrant's Quarterly Report on Form
10-QSB for the quarterly period ended May 31, 1995 filed on July 14, 1995.
(4) Incorporated by reference to the Registrant's Annual Report on Form 10-KSB
for the fiscal year ended August 31, 1995 filed on November 29, 1995.
(5) Incorporated by reference to the Registrant's Registration Statement on
Form S-8 filed on May 28, 1996, number 333-0461.
(6) Incorporated by reference to the Registrant's Quarterly Report on Form
10-QSB for the quarterly period ended May 31, 1996 filed on July 15, 1996.
(7) Incorporated by reference to the Registrant's Annual Report on Form 10-KSB
for the fiscal year ended August 31, 1996 filed on November 29, 1996.
(8) Incorporated by reference to the Registrant's Quarterly Report on Form
10-QSB for the quarterly period ended May 31, 1997 filed on July 15, 1997.
(9) Incorporated by reference to the Registrant's Annual Report on Form 10-KSB
for the fiscal year ended August 31, 1997 filed on December 1, 1997.
(10) Incorporated by reference to Exhibit 1 of the Registrant's Form 8-K filed
on January 2, 1998.
(11) Incorporated by reference to Exhibit A of Exhibit 1 of the Registrant's
Form 8-K filed on January 2, 1998.
(12) Incorporated by reference to the Registrant's Quarterly Report on Form
10-QSB for the quarterly period ended November 30, 1997 filed on January
14, 1998.
(13) Incorporated by reference to Exhibit 2.1 of the Registrant's Form 8-K filed
on March 9, 1998.
(14) Incorporated by reference to Exhibit 4.1 of the Registrant's Form 8-K filed
on March 9, 1998.
(15) Incorporated by reference to the Registrant's Quarterly Report on Form
10-QSB for the quarterly period ended May 31, 1998 filed on July 15, 1998.
(16) Incorporated by reference to the Registrant's Annual Report on Form 10-KSB
for the fiscal year ended August 31, 1998 filed on December 15, 1998.
(17) Incorporated by reference to the Registrant's Quarterly Report on Form
10-QSB for the quarterly period ended February 28, 1999 filed on April 14,
1999.
(18) Exhibit filed herewith.
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS FINANCIAL INFORMATION EXTRACTED FROM THE FROM 10-QSB FOR
OPHTHALMIC IMAGING SYSTEMS FOR THE PERIOD ENDED MAY 31, 1999 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> AUG-31-1999
<PERIOD-END> MAY-31-1999
<CASH> 147,226
<SECURITIES> 0
<RECEIVABLES> 1,067,203
<ALLOWANCES> 0
<INVENTORY> 326,579
<CURRENT-ASSETS> 1,584,097
<PP&E> 1,317,467
<DEPRECIATION> (992,959)
<TOTAL-ASSETS> 1,923,274
<CURRENT-LIABILITIES> 4,059,748
<BONDS> 0
0
0
<COMMON> 10,462,604
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 1,923,274
<SALES> 1,655,610
<TOTAL-REVENUES> 1,655,610
<CGS> 869,533
<TOTAL-COSTS> 869,533
<OTHER-EXPENSES> 910,448
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 42,502
<INCOME-PRETAX> (166,873)
<INCOME-TAX> 0
<INCOME-CONTINUING> (166,873)
<DISCONTINUED> 0
<EXTRAORDINARY> 350,000
<CHANGES> 0
<NET-INCOME> 183,127
<EPS-BASIC> 0.04
<EPS-DILUTED> 0
</TABLE>
